Clinical Trial Update: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 [Phase 3]

View source ↗

Summary

Phase 3 trial update on achieving goals after using an anti-PCSK9 antibody in statin-intolerant individuals with hyperlipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• anti-PCSK9 antibody

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2018-03-13